Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema.
作者信息
Schlueter Max, Nestler-Parr Sandra
机构信息
IQVIA, The Point, 37 North Wharf Road, London, W2 1AF, UK.
BioCryst Pharmaceuticals, 4505 Emperor Blvd., Suite 200, Durham, NC 27703, USA.
出版信息
J Comp Eff Res. 2024 May;13(5):e230165. doi: 10.57264/cer-2023-0165. Epub 2024 Mar 28.
Abstract
摘要
相似文献
1
Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema.致编辑的信：用于比较拉那度单抗和贝罗司他治疗遗传性血管性水肿的间接比较的网络荟萃分析
J Comp Eff Res. 2024 May;13(5):e230165. doi: 10.57264/cer-2023-0165. Epub 2024 Mar 28.
2
Letter in reply: network meta-analysis for indirect comparison of lanadelumab and for the treatment of hereditary angioedema.回复信：用于拉那度单抗间接比较及遗传性血管性水肿治疗的网络荟萃分析
J Comp Eff Res. 2024 May;13(5):e240041. doi: 10.57264/cer-2024-0041. Epub 2024 Apr 12.
3
Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema.网络荟萃分析比较拉那芦单抗和贝曲西班治疗遗传性血管性水肿的间接比较。
J Comp Eff Res. 2023 Jun;12(6):e220188. doi: 10.57264/cer-2022-0188. Epub 2023 May 23.
4
Efficacy of lanadelumab in angioedema due to acquired C1 inhibitor deficiency.拉那度单抗治疗获得性C1抑制物缺乏所致血管性水肿的疗效。
J Allergy Clin Immunol Pract. 2023 Mar;11(3):963-965.e1. doi: 10.1016/j.jaip.2022.10.041. Epub 2022 Nov 13.
5
Effectiveness of lanadelumab in patients with hereditary angioedema with normal C1 inhibitor and FXII mutation.拉那度单抗在C1抑制剂正常且存在FXII突变的遗传性血管性水肿患者中的疗效。
Ann Allergy Asthma Immunol. 2021 Sep;127(3):391-392. doi: 10.1016/j.anai.2021.05.028. Epub 2021 May 31.
6
Efficacy of lanadelumab in acquired angioedema with C1-inhibitor deficiency.拉那度单抗治疗C1抑制剂缺乏所致获得性血管性水肿的疗效
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2490-2491. doi: 10.1016/j.jaip.2021.01.040. Epub 2021 Feb 6.
7
Evaluation of the safety and effectiveness of berotralstat for patients with hereditary angioedema: Report of six cases.贝罗他司特对遗传性血管性水肿患者安全性和有效性的评估：6例报告
J Dermatol. 2023 Nov;50(11):1506-1508. doi: 10.1111/1346-8138.16965. Epub 2023 Sep 18.
8
Indirect treatment comparison of lanadelumab and a C1-esterase inhibitor in pediatric patients with hereditary angioedema.在患有遗传性血管性水肿的儿科患者中，lanadelumab与C1酯酶抑制剂的间接治疗比较。
J Comp Eff Res. 2025 Feb;14(2):e240110. doi: 10.57264/cer-2024-0110. Epub 2025 Jan 21.
9
Interventions for the long-term prevention of hereditary angioedema attacks.遗传性血管性水肿长期预防干预措施。
Cochrane Database Syst Rev. 2022 Nov 3;11(11):CD013403. doi: 10.1002/14651858.CD013403.pub2.
10
Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit.用于预防遗传性血管性水肿发作的拉那度单抗：一项英国真实世界审计。
Allergy. 2023 May;78(5):1369-1371. doi: 10.1111/all.15620. Epub 2022 Dec 21.
本文引用的文献
1
A guide and pragmatic considerations for applying GRADE to network meta-analysis.将GRADE应用于网状Meta分析的指南及实际考量
BMJ. 2023 Jun 27;381:e074495. doi: 10.1136/bmj-2022-074495.
2
Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema.网络荟萃分析比较拉那芦单抗和贝曲西班治疗遗传性血管性水肿的间接比较。
J Comp Eff Res. 2023 Jun;12(6):e220188. doi: 10.57264/cer-2022-0188. Epub 2023 May 23.
3
Interventions for the long-term prevention of hereditary angioedema attacks.遗传性血管性水肿长期预防干预措施。
Cochrane Database Syst Rev. 2022 Nov 3;11(11):CD013403. doi: 10.1002/14651858.CD013403.pub2.
4
Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial.日本患者口服贝拉曲司他预防遗传性血管性水肿发作：一项3期随机试验。
Allergy. 2021 Jun;76(6):1789-1799. doi: 10.1111/all.14670. Epub 2020 Dec 23.
5
Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.贝曲西班（berotralstat）每日一次口服预防遗传性血管性水肿发作的疗效：一项随机、双盲、安慰剂对照的 3 期临床试验。
J Allergy Clin Immunol. 2021 Jul;148(1):164-172.e9. doi: 10.1016/j.jaci.2020.10.015. Epub 2020 Oct 21.
6
CINeMA: An approach for assessing confidence in the results of a network meta-analysis.CINeMA：一种评估网络荟萃分析结果可信度的方法。
PLoS Med. 2020 Apr 3;17(4):e1003082. doi: 10.1371/journal.pmed.1003082. eCollection 2020 Apr.
7
Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.拉那芦单抗对比安慰剂预防遗传性血管性水肿发作的效果：一项随机临床试验。
JAMA. 2018 Nov 27;320(20):2108-2121. doi: 10.1001/jama.2018.16773.
8
Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema.口服血浆激肽释放酶抑制剂用于遗传性血管性水肿预防。
N Engl J Med. 2018 Jul 26;379(4):352-362. doi: 10.1056/NEJMoa1716995.
9
Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.抑制血浆激肽释放酶用于遗传性血管性水肿预防。
N Engl J Med. 2017 Feb 23;376(8):717-728. doi: 10.1056/NEJMoa1605767.
10
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.PRISMA 扩展声明用于报告包含健康保健干预措施网络荟萃分析的系统评价：清单和说明。
Ann Intern Med. 2015 Jun 2;162(11):777-84. doi: 10.7326/M14-2385.
Zotero 插件